Patenting inventions arising from biological research by Latimer, Matthew T
Genome Biology 2004, 6:203
c
o
m
m
e
n
t
r
e
v
i
e
w
s
r
e
p
o
r
t
s
d
e
p
o
s
i
t
e
d
 
r
e
s
e
a
r
c
h
i
n
t
e
r
a
c
t
i
o
n
s
i
n
f
o
r
m
a
t
i
o
n
r
e
f
e
r
e
e
d
 
r
e
s
e
a
r
c
h
Tutorial
Patenting inventions arising from biological research
Matthew T Latimer
Address: Moazzam & Latimer, 1474 North Point Village Center #320, Reston, VA 20194-1190, USA. E-mail: matthew.latimer@moazzamlaw.com 
Abstract
Patents are the most important way in which researchers can protect the income that might
come from ideas or technologies they have developed. This article describes the steps involved
and the considerations needed for successful granting of a patent. For instance, inventions must
be novel and not obvious, adequately described, and useful, and they should not be disclosed
publicly before a patent is applied for.
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When a researcher or group of researchers develop a novel
technique, tool, material or piece of equipment that may be
useful, they may wish to patent it in order to ensure that they
or their employer can benefit financially from their work. A
patent is defined as property right granted by a national gov-
ernment that gives the patentee the exclusive right to use,
manufacture, or sell an invention for a prescribed period of
time. For the purposes of this article, an inventor is defined
as anyone who is responsible for the idea behind the tech-
nique, tool, material or equipment; where several people are
involved, they must pursue a patent jointly, even when two
or more independent labs are involved. Inventors who are
employed by a company typically must transfer their rights
with respect to the patent to their employers. In many coun-
tries, companies may apply for patents for inventions devel-
oped by their employees. 
This article briefly explains what kinds of things can be
patented, why patents are useful, the steps in the patenting
process, the particular requirements for biotechnology
inventions and in particular inventions in genomics, bioin-
formatics and proteomics, and common problems and mis-
takes encountered during the patenting of biotechnology
inventions. Researchers in companies may also be able to get
advice from their legal department, and many universities
have a ‘technology transfer’ office that can help researchers
with the process. Although this article is not intended as
legal advice, some simple ways to maximize the value of
biotechnology patents and to avoid the common problems
and mistakes are proposed. For a more thorough discussion
and explanation of specific issues that might be encountered
during the patenting process, readers are advised to contact
a registered patent attorney or agent in the country in which
they desire patent protection (see below). In addition, good
places to start obtaining information on the patenting
process can be found in Table 1.
What kinds of biological inventions can be
patented?
Inventions arising from biological research can mean nucleic
acids, proteins, kits for the manipulation or use of DNA or
proteins in the laboratory or in medicine, diagnostic kits,
pharmaceuticals, microarrays, pieces of software for bioin-
formatics analysis, or industrial-scale processes for the pro-
duction of food or medicine. In this article, all of these types
of invention are included in the term ‘biotechnology’. For
example, biotechnology encompasses the Polymerase Chain
Reaction (PCR) and all of the machines, enzymes, buffers,
processes, and computer software to carry out PCR. This
single, multi-faceted invention has not only spawned numer-
ous patents, but numerous legal battles as well. As some of
the original PCR patents draw close to expiration, and after
many millions of dollars of expenses for both the patentee
(Roche, Basel, Switzerland) and the challengers (Du Pont
(Wilmington, USA), Promega (Madison, USA), and others),
it appears that the legal battles are subsiding, with Roche
maintaining patent coverage for the PCR process in mostcountries, including the US and European countries, but
losing coverage for enzymes (such as Taq polymerase) in
some countries, such as the US.
Biotechnology also encompasses inventions for models of
diseases and methods of drug discovery, such as the
‘Harvard Mouse’ or ‘OncoMouse’ [1]. This invention relates
to a mouse that was genetically engineered to develop
cancer, and which thus can be used to screen for compounds
that might trigger the onset of cancer and, importantly, for
drugs to combat the disease. Although most industrialized
nations permit patenting of some life-forms, this invention
brought to the forefront the issue of whether ‘complex’ or
‘higher’ life forms should be patentable. Through numerous
court battles brought by groups considering themselves
environmentalists or animal rights activists, the Harvard
Mouse patents have remained intact in some countries (such
as the US), have been restricted in scope in others (such as
European countries), and have been denied in others (such
as Canada). In view of the various differing outcomes, it
appears that the debate regarding the patentability of non-
human life forms will continue for the foreseeable future,
with questions such as “What defines a ‘complex’ life form
over a ‘simple’ life form?” and “Are all life forms equal for
patent purposes?” being debated.
Furthermore, biotechnology encompasses the diagnosis of
diseases, kits for diagnosing diseases, and therapeutic prod-
ucts. The breast-cancer predisposition gene BRCA1 and uses
of it are examples of biotechnology inventions that relate to
all of these aspects of biotechnology. Patents for this gene
and its uses have been granted in numerous countries
throughout the world; recently, however, the European
Patent Office revoked the patent directed to methods of
detecting mutations in the BRCA1 gene, concluding that the
invention lacked novelty and impeded research. That deci-
sion almost certainly will be appealed, and the continuing
battle will be closely watched by the biotechnology industry
and the law profession for an indication of how much the
European Patent Office is willing to look to asserted public
policy considerations in determining the patentability of
certain inventions.
Why consider patenting? 
As the world moves from an economy based on industry to
one based on information, protecting ideas becomes increas-
ingly important. This follows from the fact that ideas, when
captured and passed on as information, can be transferred
from one place to another much more easily and quickly
than physical objects. It also follows from the fact that the
economic value of information is greatest when it relates to
an idea, rather than a fact about a physical object, such as a
manufacturing plant or commercial product. Because infor-
mation about ideas is so valuable and so easy to obtain and
use, protecting ideas becomes a paramount concern. 
There is still much debate about the relative merits of legally
protecting scientific discoveries and inventions versus their
free and unencumbered disclosure and use. On the one
hand, legally protecting discoveries and inventions through
patents provides an incentive for researchers and businesses
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Table 1
Online sources of information on patenting 
Name Description  URL
US Patent and Trademark Office  Provides general information on preparing  http://www.uspto.gov/main/patents.htm [15]
patents and filing a patent application and obtaining 
a patent in the US
European Patent Office guide to  Provides general information on preparing  http://www.european-patent-office.org/ap_gd/index.htm [16]
applicants and filing a patent application and obtaining 
a patent in Europe
Japan Patent Office: right obtainment  Provides general information on preparing  http://www.jpo.go.jp/tetuzuki_e/index.htm [17]
procedures and filing a patent application and obtaining  
a patent in Japan
World Intellectual Property  Provides general information on preparing  http://www.wipo.int/pct/en/access/filing.htm [18]
Organization: filing PCT applications and filing an international (PCT) patent 
application
IPR Helpdesk Provides information on issues related to  http://www.ipr-helpdesk.org/controlador.jsp?cuerpo= [19]
worldwide patenting cuerpo&seccion=principal&len=en
PCT, Patent Cooperation Treaty.to undertake scientific inquiry in the hopes of a financial
benefit in return. Likewise, when one inventor patents one
solution to a particular problem, it highlights that problem
and provides an incentive for competitors to find other solu-
tions, thus bringing new products to the market rapidly. On
the other hand, permitting an inventor or company to
exclude others from making and using an invention can
result in higher costs for consumers or a delay in advances in
a field covered by a patent because of a lack of advancement
by the patent holder. Of course, regardless of the merits of a
patenting system, one may always choose to attempt to
maintain an invention secret from the world in order to
achieve an advantage in the market. But such a strategy
often backfires when the secret is lost and others are able to
use it without having to compensate the original inventor.
For companies, patenting is by far the more attractive choice
because it enables the companies to profit from the ideas of
their employees. In these times of tight budgets and financial
accountability, pursuing patent protection for scientific dis-
coveries and inventions is also important for academic
researchers, as patents can generate prestige and income for
the institute and for individual researchers.
The process of patenting always begins with an invention.
Various definitions of ‘invention’ have been used through the
ages, with most falling by the wayside for one reason or
another. For practical purposes, an invention is an idea in the
mind of the inventor of a useful machine, process, article of
manufacture, or composition of matter, where the idea is new
and is not simply an obvious derivation of something already
known. Whether that invention is patentable is a different
question altogether, because patentability is defined by statu-
tory requirements. Biotechnology patent applications must
satisfy all of the following requirements: novelty, inventive-
ness and lack of obviousness (one cannot obtain a patent for
subject matter that was publicly known or obvious at the time
the application was submitted to a patent office or ‘filed’);
adequate description and support for the claimed invention
(one must disclose enough information to permit the public
to understand, make, and use the full scope of the claimed
invention); and utility or industrial applicability (an inven-
tion must have a real-world use). Patentability is based not
only on these requirements, though, but also on the descrip-
tion of the invention in the patent document. In biological
inventions, it is often also based on the amount of experimen-
tal data available to show that the invention actually works as
envisioned by the inventor. 
Simply because one has an invention, it might not always be
advisable to patent it. Many inventions are economically
impractical either because they are too expensive to bring to
market at an attractive price, or because they appeal to such a
small portion of the public that the cost of setting up a pro-
duction facility would not be recouped. Furthermore, some
inventions, such as those relating to public health or gene
sequences, are viewed by many in the public as inappropriate
for patenting, and applications for these are struck down
during appeals brought by parties that protest the patent. In
such cases, the inventor or his company will have invested
large sums of money to obtain and defend the patent with no
legal protection to show for it in the end.
In general, any invention that is suitable for use by the
public, and that does not contravene public morality, is
patentable. Thus, most biotechnology inventions are suitable
for patenting. In view of the differing social mores from
country to country, the definition of what constitutes an
invention that contravenes public morality can differ among
countries. For example, in the US, biotechnology inventions
that have no practical use except in killing humans are con-
sidered immoral, and thus would not be suitable for patent-
ing. In many other countries, such as countries in Europe,
patenting of biotechnology inventions directed to methods
of treating humans for diseases is considered against public
morality (but they are patentable in the US). Although
patents are available in these countries for the drugs and
diagnostics used to treat or identify diseases, patents on
methods of treating, which could be enforced in such as way
as to prohibit doctors from practicing their profession and
providing life-saving services, are considered to contravene
public morality. 
So you have an invention: how do you patent it?
Once you have decided that you have a potentially
patentable invention, the next step in the process is to
prepare and submit a patent application before publicly dis-
closing the invention. Details of what needs to be included in
the application are outlined below, but the main sections are
the claims of an application, statements at the end of the
patent document that specifically point out the subject
matter that the inventor considers to be his or her patentable
invention, and the disclosure itself, which gives details and
supporting material. It is important to appreciate that a
patent is a national right: there is currently no single patent
that provides legal rights throughout the world, so it is there-
fore necessary to obtain a different patent in each country in
which patent protection is desired. Biotechnology inventions
generally require a large investment in time, labor, and
money and yet, once the invention is completed, it is rela-
tively inexpensive and easy to produce and/or practice the
invention. Because patent documents disclose the details of
how to make and use the invention, because it is now a
simple matter to search for and obtain copies of patents
issued in any country throughout the world, and because
biotechnology inventions relate to biological systems that
are available worldwide, it is important that inventors and
their employers obtain patent protection in as many differ-
ent countries as is practical. Fortunately, most industrialized
nations have similar requirements and procedures for
obtaining a biotechnology patent. Some similarities and dif-
ferences between the requirements in the US, Europe, and
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jointly by the three patent offices [2]. The similarities permit
inventors who are educated in the patenting process of one
country to be reasonably educated in the process in other
countries, and thus to minimize the cost - in both time and
money - of obtaining patents in all countries of interest. 
Although the US and a few other countries permit public dis-
closure of an invention up to one year before filing a patent
application, the vast majority of countries require absolute
novelty. Thus, inventors who desire patent protection
throughout the world must be careful to file a patent applica-
tion before publicly disclosing the invention. In addition, in
all countries except the US, inventors must file a patent
application quickly because in these countries the first to file
an application (rather than the first to invent) obtains the
right to patent the invention.
After a patent application is filed, it typically sits at a patent
office in a dormant, pending state for a period of time before
substantive examination begins (the period is at least 18
months in the US [3] and is similar in other countries). This
dormant period is due to the backlog of applications at the
patent offices that have resulted from the tremendous
increase in the number of biotechnology patents filed
recently; it also reflects the inability of most patent offices to
hire and adequately train a sufficient number of examiners
to keep pace with the rate of patent filings. Substantive
examination begins when the examiner, appointed by the
patent office, reviews the application to determine whether it
satisfies the requirements for patentability and issues a
written communication to advise the applicant of any prob-
lems. Patent examiners are employed by the patent offices;
they are trained in basic concepts of patent law and also have
training in a specialist field, such as molecular biology,
bioinformatics, protein biochemistry, or genetics. In the
initial communication to the applicant, the examiner may
reject the claims of the application for failing to satisfy one
or more laws or the requirements mentioned above. The
claims of the application, not the disclosure details, com-
prise the section of the patent application that defines the
legal right to exclusively make, use, or sell the invention, or
provide the legal right to exclude others from making, using,
or selling the invention.
Upon receipt of the written communication from the exam-
iner, the applicant has the opportunity to respond to any
objections and rejections. Typically, the applicant makes
changes to the claims, cancels or deletes claims that do not
appear to be patentable, or submits arguments against the
examiner’s objections and rejections. If the response by the
applicant does not convince the examiner that the applica-
tion is patentable, the applicant must choose whether to
abandon the application, to continue to argue for patentabil-
ity, or to appeal against the examiner’s decision to a supervi-
sory board that has power to overrule the examiner. If the
applicant is not satisfied with the decision of the supervisory
board, he or she can take the appeal to the national courts,
but this is very costly in terms of both money and time. A
schematic overview of the patenting process in the US and
Europe is depicted in Figure 1. 
Why are biotechnology inventions difficult to
patent?
Researchers who have biological inventions are often sur-
prised by the difficulties they encounter when trying to
patent their inventions, compared with the experience of
their counterparts in the fields of electronics and mechanics.
These difficulties arise because a higher standard of scrutiny
is applied to inventions in biotechnology because they are
more complex and unpredictable (see below) [4]. For
example, for patents including the sequences of genes or
proteins, the current policy of the US Patent and Trademark
Office is to require disclosure of “a representative number of
examples” of homologs, either from the same organism or
from different organisms, of the gene or protein before a
patent generically covering it will be issued [5]. Although the
European Patent Office does not officially have such a policy,
in cases in which the essence of the invention is the achieve-
ment of a technical effect, it is often necessary to provide a
sufficient number of examples to show that the effect can be
achieved in most - if not all - instances of the use of the
invention in a particular field. For example, if one wished to
patent an antibody for use in detecting all cancer cells, one
would probably need to provide examples showing that the
antibody could detect a variety of different cancer cells,
including solid tumor cells, and lymphoma cells, and
leukemia cells.
Patent offices invariably justify their higher standard of
scrutiny for biotechnology inventions by asserting that bio-
logical systems are complex and unpredictable and that
complex and unpredictable technologies should require a
greater amount of data and disclosure. Although this asser-
tion might be an inaccurate generalization, one must contin-
ually be mindful of the policy before and during the
patenting process in order to improve the likelihood of
obtaining a patent with commercial value.
How to get the best-value patent
In view of the time and money required to obtain patent pro-
tection for a biotechnology invention with the potential for
international success, it is important to maximize the value
that will be returned on the investment. The following are
some key areas on which applicants for biotechnology patents
should focus in order to maximize the return on their invest-
ment. First and foremost, applicants should not disclose the
invention publicly until a patent application has been filed in
at least one country. A public disclosure includes absolutely
any non-confidential disclosure to any person outside of the
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and it can include disclosure by a person other than the
inventor. Thus, public disclosure includes publication in a
journal (whether print or web-based), presentation of a
poster or abstract at a scientific or trade meeting, discussions
with others in the field at a meeting or over the telephone,
and discussion or mention in an e-mail. The disclosure,
however, must be ‘enabling’. That is, the information dis-
closed publicly must be of such a quality and quantity that
someone with an ordinary level of skill in the field could
make and use the invention. Thus, a mere statement that a
company has developed an algorithm to identify and distin-
guish clinical isolates of a particular pathogen would be
unlikely to constitute a patent-defeating public disclosure;
more details of the steps in the process would be needed for
an ordinary person to arrive at the particular algorithm. Con-
fidential disclosures, such as those between employees of the
same company, between an inventor and his or her attorney,
or between those covered by a legal agreement, such as a non-
disclosure agreement, should not defeat the patentability of
an invention. As mentioned above, in most countries, public
disclosure of the invention before filing a patent application
bars the right to obtain a patent on the invention. In addition,
disclosure of improvements or new data relating to the inven-
tion could rule out a patent on the new subject matter; care
must therefore be taken when discussing any aspect of an
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Figure 1
A schematic representation of the typical actions taken during the examination process of a patent application before (a) the US Patent and Trademark
Office and (b) the European Patent Office. Dashed lines indicate alternative actions that are possible at each stage; solid lines indicate that the indicated
action necessarily follows the previous one. It can be seen that two steps are available in Europe but not in the US: an optional oral hearing before the
patent is allowed, in which applicants may argue orally for the patentability of their inventions before a panel of examiners, and an opposition period after
the application is allowed, in which the public may oppose the patent. ‘Restriction’ and ‘Lack of unity’ are equivalent procedures through which the patent
offices require an applicant to divide a single application into two separate patent applications (an ‘original’ and a ‘divisional’), on the basis of a conclusion
that the single original application disclosed and claimed two distinct inventions. An ‘office action’ is a written report issued by the examiner regarding
the patentability of the claimed invention. Upon concluding that an application is patentable, the examiner will ‘allow’ the application. In the US, the
issuing of the patent typically follows allowance after completion of certain simple formalities, whereas in Europe the issuing of a patent does not occur
for several months; during this time, members of the public may oppose the patent and the patent applicant must substantively defend the patentability of
the invention. 
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(a) (b)  US  Europeinvention in public. As a general rule, to avoid the loss of
rights to a patent, any information that could serve as the
basis for a patent should be included in a patent application -
and filed in a patent office - before that information is made
available to the public.
Applicants should also make a thorough search of patent and
scientific databases before preparing and filing a patent
application, to determine whether the subject matter of the
invention has already been disclosed. In searching, one
should focus not only on the specific commercial embodi-
ment of the invention, but on broader aspects as well, so as
to find out how broad the patent could be. Time and money
spent at this stage is well spent, because the results of the
search can guide applicants in both preparing the patent
application and entering the marketplace with a viable
product. Numerous free and commercial public databases
are available for searching: a list of some commonly used
ones is shown in Table 2.
Applicants should also consider filing the application under
the Patent Cooperation Treaty (PCT), which gives applicants
access to over 100 countries for a single filing fee and pro-
vides at least 30 months in which to decide whether to
proceed with the application in one, some, or all of the treaty
countries [6]. In addition, under the PCT a single opinion by
a patent examiner on other related patents and the
patentability of the invention is issued before a decision by
an applicant to proceed with the application in commercially
important countries must be made [7]. If this opinion uncov-
ers one or more publications that negate the patentability of
the invention, the applicant can abandon the application
without having incurred the filing fees for the commercially
important countries. The 30-month delay also lets the appli-
cant determine whether the invention is commercially feasi-
ble before having to pay the filing fees for all commercially
important countries.
I had an invention - why didn’t I get a patent
that is worth anything?
The reasons why a biotechnology patent application might
never become a patent or might have limited commercial
value fall into two main categories: inadequate research and
preparation of the application before filing, and inadequate
data to support a commercially valuable patent. The single
most common reason for failure is because of insufficient
novelty or inventiveness, almost invariably because a thor-
ough search of patent and scientific databases was not done.
An applicant in this position must either give up the idea of a
patent or spend considerable additional resources attempt-
ing to salvage the application. To avoid this common pitfall,
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Table 2
Databases of patents and scientific publications
Name Description  URL
United States Patent and Trademark  For searching and printing US patents and  http://www.uspto.gov/patft/index.html [20]
Office: patent full-text and full-page  published US applications
image database
European Patent Office: esp@cenet For searching and printing worldwide patents  http://ep.espacenet.com/search97cgi/s97_cgi.exe?Action= [21]
and patent publications FormGen&Template=ep/EN/home.hts
Japan Patent Office: quick guide For searching and printing Japanese patents  http://www.jpo.go.jp/quick_e/index_search.htm [22]
and patent publications
World Intellectual Property  For searching and printing international  http://www.wipo.int/ipdl/en/index.jsp [23]
Organization: Intellectual Property  (PCT) applications
Digital Library
NCBI PubMed Database of biomedical research articles http://www.ncbi.nlm.nih.gov/entrez/query.fcgi [24]
Thomson Derwent A collection of databases of biotechnology  http://www.derwent.com/ [25]
research articles for fee-based searching 
and retrieval
Chemical Abstracts Databases A collection of databases of chemical and  http://www.cas.org/casdb.html [26]
pharmaceutical research articles and 
compounds for fee-based searching and 
retrieval
STN A collection of databases of biotechnology  http://www.cas.org/stn.html [27]
research articles for fee-based searching 
and retrieval
Google Scholar  A system for searching academic articles and http://scholar.google.com/ [28]
other scholarly publications, and their citations
Genome Biology 2004, 6:203one should not only perform a thorough search of public
databases but also craft the application so as to avoid overlap
with similar publications.
A second common pitfall is disclosure of too little informa-
tion about the claimed invention. Biotechnology patents now
typically cover only what is precisely disclosed and described
in the application. Likewise, the examiner’s judgment of the
invention’s utility depends critically on the amount of infor-
mation disclosed. Examiners in the US Patent and Trade-
mark Office rely heavily on strict written guidelines on
description and utility when determining whether there is
adequate disclosure of information [5,8]. European examin-
ers also rely on guidelines and often also insist that each
word in the claims of an application is present in the text of
the patent disclosure and is used in precisely the same way
as it is used in the claims. Thus, often no generalizations or
synonyms are permitted in the claims [9]. More often than
not, examiners in most countries look specifically at the
examples provided - and any nucleotide and amino-acid
sequences disclosed - to determine the breadth of the claims
that will be issued in the patent.
The problem of disclosing too little is especially prevalent
when an applicant relies on a patent document from another
country to provide a ‘priority’ date for an invention, the date
on which the first patent describing it was filed. Certain
countries permit applicants to claim priority on the basis of
the date that a foreign patent application was filed. This pri-
ority date is considered (for the purposes of identifying pub-
lications that defeat the novelty or inventiveness of the
invention) as the filing date of an application somewhere in
the world, even though the actual patent application being
examined may have been filed up to twelve months after that
date. On the one hand, this mechanism benefits applicants
because it allows them to file a single application in one
country and wait up to one year to file applications in other
countries. On the other hand, it is a trap for the unwary
biotechnology applicant who prepares and files a priority
application in such a way as to satisfy the legal requirements
of only the individual country in which it is first filed. Unfor-
tunately for many applicants, the legal requirements for that
first country might not be as stringent as those of other
countries, and the scope of the patents in the other countries
might be limited accordingly on the basis of an inadequate
disclosure. For example, patent applications in some coun-
tries, such as some in the Pacific Rim or South Pacific
regions, are acceptable if they disclose the general concept of
the invention and provide a single specific example of the
general concept. In the US, however, such a disclosure, if
relating to a biotechnology application, would probably not
be sufficient to support a patent covering the general
concept. Thus, the US Patent and Trademark Office would
probably not recognize the ‘priority’ date as a valid date for
broad claims, and they could limit the breadth of the claims
to the specific example if the examiner found a relevant
publication that preceded the actual US filing date. Alterna-
tively, if the applicant attempts to add subject matter to the
application when it is filed in the other countries, that
subject matter will probably not be granted the filing date of
the priority document. Information that became publicly
available between the dates of filing of the first (priority)
application and the second application may be used to defeat
the patentability of the second application [10,11].
The cure for this heightened disclosure requirement is
obvious, but it is not necessarily simple: one should disclose
as much information and data in the first-filed application as
is needed to satisfy the requirements of all countries.
Prudent applicants now disclose many ranges, data points,
and other parameters to support varying claim scopes. For
example, applications directed to microarrays often include
the use of nucleic acids bound to a solid support, and the
number of different sequences present or the number and
location of duplicate copies of a single sequence on the solid
support is important. In such a situation, it is wise for the
applicant to disclose a variety of numbers and locations. The
examiner will then be able to differentiate the invention
from other relevant publications that might include a
general disclosure of the concept, but not the specific data
that are important in making the microarray useful. 
Prudent applicants will also provide as much relevant data
as possible, covering as many chemical compounds or bio-
logical species as they can. Because the breadth - and thus
the value - of a biotechnology patent now depends essen-
tially on the amount of information presented in an applica-
tion, it is best to disclose and claim all possible aspects of an
invention, not simply the core of the invention. Of course, if
an applicant recognizes that the invention is broader than
implied by the specific data available at the time of preparing
the application, he or she must choose to either support the
breadth of the invention with scientific reasoning, and argue
to the examiner that the reasoning is sound and sufficient to
warrant broad coverage, or forego broad claims and file
additional patent applications when data supporting the
broader aspects become available. For example, imagine that
members of a research group file a patent application that
states that the invention covers all antisense molecules that
disrupt expression of a gene, but provides specific examples
of only two antisense molecules. If they can convince the
examiner that the two examples provide enough information
for other scientists to create other antisense molecules with
the described function, they might obtain a broad patent
covering all antisense molecules that disrupt expression of
the gene. But if the applicants are unable to convince the
examiner that the two specific examples provide enough
information to develop other functional antisense molecules,
they may have to accept a narrow patent that covers only the
two examples. They may then file another application to add
further examples of functional antisense molecules and
argue that the additional examples, in conjunction with the
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tist to create other functional antisense molecules. 
In contrast to the problem of disclosing too little, applicants
often find that they have claimed too little. This pitfall typi-
cally stems from a failure of the inventor to appreciate fully
the true scope of the invention, or a failure to claim the
invention in terms that cover its full scope. Even when
inventors recognize the true breadth of their inventions, they
often incorrectly believe that claims to the ‘core’ of the tech-
nology provide coverage for the full scope of all aspects of
the invention; unfortunately, narrowly focused claims do not
necessarily cover all aspects of an invention. In addition,
narrowly focused claims are often easy for the public (or
competitors) to avoid - in other words, they can market a
product that is very similar but escapes infringement and
thus the need to pay royalties by being slightly different. For
example, a patent for a microarray containing “5,000 indi-
vidual oligonucleotides that are specific for an expressed
Escherichia coli gene” could be designed around by making
a microarray containing 6,000 individual oligonucleotides
or by a microarray containing 5,000 individual oligo-
nucleotides, one thousand of which bind equally well to E.
coli and Salmonella typhimurium genes and thus are not
specific for E. coli genes. On the other hand, a broader claim,
such as one to a microarray containing “at least 1,000
oligonucleotides that individually either perfectly match, are
perfectly complementary, or bind under high stringency con-
ditions to a sequence within at least one expressed E. coli
gene” would be much more difficult for a competitor to
design around and avoid. By failing to consider and claim
the broad applicability of their inventions, applicants often
obtain patents that cover too little subject matter.
With the increasing emphasis that patent offices are placing
on the utility of biotechnology inventions, applicants are
now finding that applications that fail to identify specifically
the utility of the invention are rejected [12]. For example,
applicants typically must now identify the specific function
of a cloned gene or its encoded protein and, further, must
identify an industrial or ‘real world’ use for the gene and/or
the protein it encodes. Likewise, applicants claiming a thera-
peutic product or method must typically present data
showing that a therapeutic result can be achieved. Prudent
applicants now delay filing patent applications until they can
identify a specific industrial or other utility for their inven-
tion. The most cautious, and most successful, delay filing
until data are available to support the utility clearly.
Historically, many biotechnology inventions have been
based on gene cloning and the expression of cloned genes,
and patents on such inventions necessarily rely on the
sequences of the genes and encoded proteins. For various
reasons, a significant number of patent applications are filed
with incorrect nucleotide or amino-acid sequences. These
applications can be commercially useless if the errors are not
corrected before a patent is issued. Although it is generally
not possible to submit a new, different sequence after an
application has been filed, many countries provide a mecha-
nism for correcting sequences or for claiming nucleic acids
or proteins as part of a patent without presenting their
sequences. To take advantage of this mechanism, it is critical
that the applicant ensures that biological material contain-
ing the nucleic acid or protein is deposited in an internation-
ally recognized depository and that the biological material is
identified specifically in the application. By taking these
steps, an applicant may later either correct the sequences or
simply claim the deposited biological material as the basis
for a patent rather than the published sequences. In the
absence of such steps, it is difficult or impossible to correct
errors or claim the biological material as containing the
invention [13,14].
Another common trap for unwary applicants is failure to dis-
close the computer software used to analyze sequence data.
There are now numerous programs available for this, and
they can give differing results from the same sequence infor-
mation. Accordingly, without information about the pro-
grams used to analyze sequence data, it could be difficult, if
not impossible, for the public to reproduce the analysis and
to determine whether certain activities infringe a patent.
This shortcoming can serve as a basis for rejection of the
application and thus the computer programs used and the
parameters used in each analysis should always be disclosed.
Are genomic, proteomic and bioinformatic
patents worth the trouble?
There are some specific issues that should be considered
when deciding to patent inventions in genomics, proteomics,
and bioinformatics. Firstly, one must always remember that
these fields rely, at least to some extent, on both biotechnol-
ogy and either electronics or physics, and that most patent
examiners are not educated in more than one scientific or
engineering field. Thus, examination of the patent applica-
tion can be delayed because the examiner needs to consult
with other examiners in a different area of science. Worse
yet, an inadequate examination might occur if an examiner
lacking the necessary education does not consult with
another examiner. In essence, the greatest economic value of
inventions in genomics and proteomics is in the information
they can provide, such as the genes and proteins involved in
diseases and disorders, nucleotide sequences bound by key
proteins, and candidates for drug targets. Because patent
applications typically do not identify all of these genes, pro-
teins, target sequences, and drugs, they do not cover the
greatest economic value of the invention. Likewise,
genomics and proteomics inventions typically rely on a large
number of individual pieces of data. As discussed above, to
ensure that one obtains patents in all of the most economi-
cally important regions of the world, an applicant should
disclose the primary sequence of all nucleic-acid and protein
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obtaining each. By disclosing all of this information in the
application, however, applicants make it easy for others to
‘design around’ the patent, that is, to design a product or
method that does not infringe by simply adding, deleting, or
altering one or a few components. This result is clearly not in
the best interest of the applicant. Thus, if it appears that a
patent with broad, commercially valuable claims is not
obtainable, the applicant might want to consider protecting
the invention through other means.
One way to avoid many of the problems that arise in patent-
ing biotechnology inventions is to maintain such inventions
as trade secrets. In essence, a trade secret is information that
provides economic value to its holder from not being known
by other people. Typically, the information provides an
advantage in the marketplace for the holder over any com-
petitors. This means that revenue streams can be generated
by practicing the inventions in a secure environment, mar-
keting the inventions without disclosing how they are made
or how the data provided to customers are generated, or
licensing them to others without disclosing the specific
sequences, data points, or algorithms. Competitors will
therefore find it difficult to produce similar products by
making small modifications to the design or ‘reverse engi-
neering’ (copying of a competitor’s technology by disassem-
bling a product and reproducing its individual parts to create
an exact copy or functional equivalent), and potentially long-
lived, stable revenue streams can be secured without the
need for patenting.
In conclusion, patents are important for protecting the right
of inventors to profit from their research. The patenting
process can be complex and there are numerous traps for the
unwary scientist, but a basic understanding of the process
can make the important issues clear. Furthermore, although
you can never predict a successful outcome, avoiding the
common pitfalls can significantly reduce the cost of obtain-
ing patents - and the frustration encountered during the
process - and can increase the chances of obtaining a broad,
commercially valuable patent. 
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